Karyopharm Therapeutics | KPTI - Bénéfice Avant Impôts





Bénéfice Avant Impôts Changement Date
AbbVie USD 4.38B 1.92B 2025-09
Abbott USD 2.36B 178M 2025-12
Amgen USD 3.92B 2.35B 2025-09
AstraZeneca USD 3.24B 117M 2025-09
BioCryst Pharmaceuticals USD -86.95M 73.5M 2024-12
Bristol-Myers Squibb USD 3.11B 1.34B 2025-09
Eli Lilly USD 7.23B 456M 2025-09
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Incyte USD 389.94M 92.37M 2025-12
J&J USD 4.97B 2.53B 2025-12
Karyopharm Therapeutics USD -30.89M 1.16M 2024-12
MacroGenics USD 16.82M 52.97M 2025-09
Merck USD 6.74B 22M 2025-09
Nektar Therapeutics USD -37.05M 15.27M 2024-09
Novartis USD 4.2B 335M 2025-09
Novartis USD 5.17B 637M 2025-09
Pfizer USD 3.33B 290M 2025-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Takeda JPY 133.86B 105.69B 2025-12
Tectonic Therapeutic USD -19.04M 25K 2025-09
TG Therapeutics USD 45.09M 19.18M 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Xencor USD -4.27M 1.76M 2025-12